Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued on Monday,Benzinga reports. They presently have a $15.00 price target on the stock.

Several other research firms also recently commented on IMRX. Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Chardan Capital restated a “buy” rating and set a $13.00 price target on shares of Immuneering in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $12.80.

Immuneering Price Performance

Shares of IMRX opened at $1.95 on Monday. Immuneering has a one year low of $1.00 and a one year high of $7.68. The company has a market cap of $60.55 million, a PE ratio of -0.99 and a beta of -0.34. The stock has a 50-day moving average of $2.05 and a 200-day moving average of $1.79.

Institutional Investors Weigh In On Immuneering

A number of institutional investors and hedge funds have recently bought and sold shares of IMRX. XTX Topco Ltd boosted its holdings in Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after acquiring an additional 9,274 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Immuneering by 21.4% during the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after purchasing an additional 9,400 shares in the last quarter. Corsair Capital Management L.P. purchased a new position in Immuneering during the third quarter worth about $25,000. Vontobel Holding Ltd. purchased a new position in Immuneering during the third quarter worth about $25,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Immuneering in the 2nd quarter worth about $44,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.